- CONTACT US
- AFS
- Business
- Bussiness
- Car
- Career
- Celebrity
- Digital Products
- Education
- Entertainment
- Fashion
- Film
- Food
- Fun
- Games
- General Health
- Health
- Health Awareness
- Healthy
- Healthy Lifestyle
- History Facts
- Household Appliances
- Internet
- Investment
- Law
- Lifestyle
- Loans&Mortgages
- Luxury Life Style
- movie
- Music
- Nature
- News
- Opinion
- Pet
- Plant
- Politics
- Recommends
- Science
- Self-care
- services
- Smart Phone
- Sports
- Style
- Technology
- tire
- Travel
- US
- World

Thousands of bottles of a commonly used prescription drug to treat hypertension has been recalled for possible contamination with another drug.
Glenmark Pharmaceuticals Inc., which has U.S. headquarters in Elmwood Park, New Jersey, has recalled multiple lots of bisoprolol fumarate and hydrochlorothiazide tablets (brand name Ziac), because the tablets may have been cross contaminated with other products, according to a recall report published online by the Food and Drug Administration.
The global drug maker, which is headquartered in Mumbai, India, said testing of reserve samples showed presence of traces of ezetimibe, a cholesterol drug the company also produces, according to the recall, posted Dec. 1.
Vaccine directive: RFK Jr. panel ends recommendation of hepatitis b vaccine for newborns
The FDA classified the recall with a Class III risk level, which suggests "use of or exposure to a violative product is not likely to cause adverse health consequences," according to the agency.
Bisoprolol/hydrochlorothiazide blocks beta-1 receptors in your heart, allowing the heart to beat normally, according to WebMD. The drug also increases urination to remove sodium and water from the body, as well as relaxes blood vessels – to help lower blood pressure and help to reduce heart attack and stroke risk.
USA TODAY Recall Database: Search vehicle, product and food recalls
What blood pressure medicine is being recalled?
The recall involves an undeclared number of lots of tablets, from 2.5 mg to 6.25 mg dosages, in various sized bottles, manufactured in Madhya Pradesh, India for Glenmark Pharmaceuticals, Inc., USA.
These lots were recalled:
30-tablet bottles, NDC-68462-878-30. Lot 17232401, exp. 11/2025.
100-tablet bottles, NDC-68462-878-01. Lot 17232401, exp. 11/2025.
500-tablet bottles, NDC-68462-878-05. Lots 17232401, exp. 11/2025 and 17240974, exp. 05/2026.
USA TODAY has reached out to Glenmark Pharmaceuticals. Neither Glenmark nor the FDA have issued guidance on what to do with the recalled tablets.
But according to GoodRx, anyone affected by a drug recall is advised to check their medication's lot number, contact their pharmacist as well as their prescriber and throw away the recalled medication.
Contributing: Natalie Neysa Alund
Mike Snider is a national trending news reporter for USA TODAY. You can follow him on Threads, Bluesky, X and email him at mikegsnider & @mikegsnider.bsky.social & @mikesnider & [email protected]
What's everyone talking about? Sign up for our trending newsletter to get the latest news of the day
This article originally appeared on USA TODAY: Blood pressure drug recall linked to possible cross-contamination
LATEST POSTS
- 1
Deadly attack on kindergarten reported in Sudan - 2
What’s your chronotype? Knowing whether you’re a night owl or an early bird could help you do better on tests and avoid scams - 3
Single women risk rape and exploitation in search for better life in Europe - 4
At least 11 killed in South Africa mass shooting - 5
Herzog, German Chancellor Merz discuss final Gaza hostage, Arrow 3 exchange in Jerusalem
Emergent Cold LatAm opens state-of-the-art cold storage hub in Guadalajara
Peloton recalls more than 800,000 bikes after broken seat posts injure users
Wizz CEO: We’re going to invest $1 b. in Israeli market
Germany and trade unions kick off tough public-sector wage talks
Europe's powerful Ariane 6 rocket launches Sentinel-1D Earth-observation satellite to orbit (video)
Peloton recalls more than 800,000 bikes after broken seat posts injure users
Top German court to rule on claims by Wirecard shareholders
Moderna to complete US mRNA manufacturing network with $140 million investment
Novo Nordisk gears up for December Ozempic launch in India, sources say











